Shares of Zogenix ZGNX rose in after-market trading after the company reported Q2 results.
Quarterly Results
Earnings per share decreased 9.38% year over year to ($1.05), which missed the estimate of ($0.94).
Revenue of $18,789,000 higher by 1720.64% from the same period last year, which beat the estimate of $17,080,000.
Guidance
Zogenix hasn't issued any earnings guidance for the time being.
Revenue guidance hasn't been issued by the company for now.
How To Listen To The Conference Call
Date: Aug 05, 2021
Time: 04:30 PM
ET Webcast URL: http://public.viavid.com/index.php?id=145894
Price Action
Company's 52-week high was at $25.88
52-week low: $15.72
Price action over last quarter: down 12.29%
Company Description
Zogenix Inc is engaged in developing and commercializing therapeutic solutions for people living with serious and life-threatening rare CNS disorders and medical conditions. Its product candidate includes ZX008, low-dose fenfluramine for the treatment of Dravet syndrome, LGS, and potentially other rare and catastrophic epilepsy disorders.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
